Whitehawk Therapeutics (WHWK) investor relations material

Portfolio and strategy

• Advancing a portfolio of next-generation antibody drug conjugates (ADCs) targeting PTK7, MUC16, and SEZ6, with a focus on high-potential, clinically validated cancer targets.

• Emphasizing differentiated science, proven leadership, and execution-focused operations, supported by a strong management team and top-tier investors.

• Over $160 million in cash provides runway into 2028, supporting key clinical milestones for all three programs.

• Rapid clinical advancement planned, with INDs for HWK-007 and HWK-016 expected this quarter and HWK-206 by mid-next year.

• Multiple expansion opportunities exist for each asset, with initial focus on indications with established clinical precedent.

Technology platform and differentiation

• ADC platform features novel topo-1 inhibitor payload, highly stable linker chemistry, and carbon-bridge cysteine repairing for enhanced stability.

• Unique bioconjugation method restores antibody stability and reduces free payload release, minimizing off-target toxicity.

• Proprietary modified exatecan payload offers potent tumor killing with reduced hematological toxicity, addressing neutropenia seen in other topo-1 ADCs.

• Preclinical data show 3-10x greater potency, 5-25x lower free payload in plasma, and 2-3x higher safety margin compared to conventional topo-1 ADCs.

• Tumor-specific delivery and controlled intracellular payload release further differentiate the platform.

Clinical development and targets

• HWK-007 (PTK7-targeted) shows higher affinity, improved tumor engagement, and superior preclinical efficacy versus first-generation ADCs.

• HWK-016 (MUC16-targeted) uniquely targets the non-shed, membrane-bound portion, overcoming antigen sink and showing superior tumor inhibition in preclinical models.

• HWK-206 (SEZ6-targeted) employs a biparatopic approach, aiming for leadership in this validated target.

• Initial clinical focus for HWK-007: lung, ovarian, and endometrial cancers; for HWK-016: ovarian and endometrial cancers.

• Earliest clinical data readouts for HWK-007 and HWK-016 expected in early 2027, with proof-of-concept data from a China partner anticipated in 2026.